Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma

Published:2020-12-10 Issue:12 Volume:6 Page:e204930
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sonbol Mohamad Bassam¹,Riaz Irbaz Bin²,Naqvi Syed Arsalan Ahmed³,Almquist Daniel R.¹,Mina Syeda⁴,Almasri Jehad⁵⁶,Shah Shiv⁷,Almader-Douglas Diana⁸,Uson Junior Pedro Luiz Serrano¹,Mahipal Amit²,Wee Wen²,Jin Zhaohui²,Mody Kabir⁹,Starr Jason⁹,Borad Mitesh J.¹,Ahn Daniel H.¹,Murad M. Hassan⁶,Bekaii-Saab Tanios¹

Affiliation:

1. Mayo Clinic Cancer Center, Phoenix, Arizona

2. Mayo Clinic Cancer Center, Rochester, Minnesota

3. Dow University of Health Sciences, Karachi, Pakistan

4. Department of Internal Medicine, Mayo Clinic, Arizona

5. Piedmont Athens Regional Hospital, Athens, Georgia

6. Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota

7. Mayo Clinic Alix School of Medicine, Scottsdale, Arizona

8. Mayo Clinic Libraries, Mayo Clinic, Phoenix, Arizona

9. Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2771837/jamaoncology_sonbol_2020_oi_200079_1606943509.8932.pdf

Reference36 articles.

1. Sorafenib in advanced hepatocellular carcinoma.;Llovet;N Engl J Med,2008

2. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.;Abou-Alfa;N Engl J Med,2018

3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.;Bruix;Lancet,2017

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.;Kudo;Lancet,2018

5. KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC).;Finn;Annals of Oncology.,2017

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

2. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study;International Immunopharmacology;2024-09

3. CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma;Translational Oncology;2024-09

4. ADH4—a potential prognostic marker for hepatocellular carcinoma with possible immune-related implications;BMC Cancer;2024-08-01

5. Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma;Clinics and Research in Hepatology and Gastroenterology;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3